-
公开(公告)号:US20130338157A1
公开(公告)日:2013-12-19
申请号:US13774938
申请日:2013-02-22
申请人: Penglie Zhang , Andrew M.K. Pennell , John J. Kim Wright , Wei Chen , Manmohan R. Leleti , Yandong Li , Lianfa Li , Yuan Xu , Mark M. Gleason , Yibin Zeng , Kevin Lloyd Greenman
发明人: Penglie Zhang , Andrew M.K. Pennell , John J. Kim Wright , Wei Chen , Manmohan R. Leleti , Yandong Li , Lianfa Li , Yuan Xu , Mark M. Gleason , Yibin Zeng , Kevin Lloyd Greenman
IPC分类号: C07D471/04 , C07D487/04
CPC分类号: A61K31/496 , A61K31/5377 , A61K45/06 , C07D471/04 , C07D487/04
摘要: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
-
公开(公告)号:US20110098308A1
公开(公告)日:2011-04-28
申请号:US12829312
申请日:2010-07-01
申请人: Penglie Zhang , Andrew M.K. Pennell , John J. Kim Wright , Wei Chen , Manmohan R. Leleti , Yandong Li , Lianfa Li , Yuan Xu , Mark M. Gleason , Yibin Zeng , Kevin Lloyd Greenman
发明人: Penglie Zhang , Andrew M.K. Pennell , John J. Kim Wright , Wei Chen , Manmohan R. Leleti , Yandong Li , Lianfa Li , Yuan Xu , Mark M. Gleason , Yibin Zeng , Kevin Lloyd Greenman
IPC分类号: A61K31/497 , C07D471/04 , A61P19/02 , A61P25/00 , A61P17/00 , A61P1/00 , A61P37/08 , A61P25/16 , A61P25/28
CPC分类号: A61K31/496 , A61K31/5377 , A61K45/06 , C07D471/04 , C07D487/04
摘要: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
摘要翻译: 提供了作为CCR1受体的有效拮抗剂并具有体内抗炎活性的化合物。 化合物通常为芳基哌嗪衍生物,并且可用于药物组合物,用于治疗CCR1介导的疾病的方法,以及用于鉴定竞争性CCR1拮抗剂的测定中的对照。
-
公开(公告)号:US20090252779A1
公开(公告)日:2009-10-08
申请号:US12418516
申请日:2009-04-03
申请人: Penglie Zhang , Andrew M.K. Pennell , John J. Kim Wright , Wei Chen , Manmohan R. Leleti , Yandong Li , Lianfa Li , Yuan Xu
发明人: Penglie Zhang , Andrew M.K. Pennell , John J. Kim Wright , Wei Chen , Manmohan R. Leleti , Yandong Li , Lianfa Li , Yuan Xu
IPC分类号: A61F2/04 , C07D471/04 , A61K31/497 , A61K31/5377
CPC分类号: C07D471/04
摘要: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
摘要翻译: 提供了作为CCR1受体的有效拮抗剂并具有体内抗炎活性的化合物。 化合物通常为芳基哌嗪衍生物,并且可用于药物组合物,用于治疗CCR1介导的疾病的方法,以及用于鉴定竞争性CCR1拮抗剂的测定中的对照。
-
公开(公告)号:US20100113472A1
公开(公告)日:2010-05-06
申请号:US12611766
申请日:2009-11-03
申请人: Daniel Dairaghi , Lianfa Li , Andrew M.K. Pennell , Penglie Zhang
发明人: Daniel Dairaghi , Lianfa Li , Andrew M.K. Pennell , Penglie Zhang
IPC分类号: A61K31/497 , A61P19/10 , A61P35/04
CPC分类号: A61K31/496
摘要: Methods are provided for the treatment of osteoporosis and multiple myeloma, using 3-imidazoyl-pyrazolo[3,4-b]pyridine compounds.
摘要翻译: 提供了使用3-咪唑基 - 吡唑并[3,4-b]吡啶化合物治疗骨质疏松症和多发性骨髓瘤的方法。
-
公开(公告)号:US20080300257A1
公开(公告)日:2008-12-04
申请号:US12124894
申请日:2008-05-21
申请人: Lianfa Li , Andrew M.K. Pennell , Penglie Zhang
发明人: Lianfa Li , Andrew M.K. Pennell , Penglie Zhang
IPC分类号: A61K31/496 , C07D471/04 , A61P37/02 , A61P29/00 , A61P25/28 , A61P25/16
CPC分类号: C07D471/04
摘要: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are 3-imidazoyl-pyrazolo[3,4-b]pyridine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.
摘要翻译: 提供了作为CCR1受体的有效拮抗剂并具有体内抗炎活性的化合物。 化合物是3-咪唑基 - 吡唑并[3,4-b]吡啶衍生物,可用于药物组合物,治疗CCR1介导的疾病的方法,以及用于鉴定竞争性CCR1拮抗剂的测定中的对照。
-
公开(公告)号:US20120010214A1
公开(公告)日:2012-01-12
申请号:US13103993
申请日:2011-05-09
申请人: Lianfa Li , Andrew M.K. Pennell , Penglie Zhang
发明人: Lianfa Li , Andrew M.K. Pennell , Penglie Zhang
IPC分类号: A61K31/496 , A61P19/02 , A61P25/00 , A61P37/06 , A61P17/06 , A61P1/00 , A61P11/06 , A61P25/28 , A61P25/16 , C07D401/14 , A61P17/00
CPC分类号: C07D471/04
摘要: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are 3-imidazoyl-pyrazolo[3,4-b]pyridine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.
摘要翻译: 提供了作为CCR1受体的有效拮抗剂并具有体内抗炎活性的化合物。 化合物是3-咪唑基 - 吡唑并[3,4-b]吡啶衍生物,可用于药物组合物,治疗CCR1介导的疾病的方法,以及用于鉴定竞争性CCR1拮抗剂的测定中的对照。
-
公开(公告)号:US07960388B2
公开(公告)日:2011-06-14
申请号:US12617620
申请日:2009-11-12
申请人: Lianfa Li , Andrew M.K. Pennell , Penglie Zhang
发明人: Lianfa Li , Andrew M.K. Pennell , Penglie Zhang
IPC分类号: A61K31/437 , A61P19/02
CPC分类号: C07D471/04
摘要: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are 3-imidazoyl-pyrazolo[3,4-b]pyridine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.
摘要翻译: 提供了作为CCR1受体的有效拮抗剂并具有体内抗炎活性的化合物。 化合物是3-咪唑基 - 吡唑并[3,4-b]吡啶衍生物,可用于药物组合物,治疗CCR1介导的疾病的方法,以及用于鉴定竞争性CCR1拮抗剂的测定中的对照。
-
公开(公告)号:US20100173911A1
公开(公告)日:2010-07-08
申请号:US12617620
申请日:2009-11-12
申请人: Lianfa Li , Andrew M.K. Pennell , Penglie Zhang
发明人: Lianfa Li , Andrew M.K. Pennell , Penglie Zhang
IPC分类号: A61K31/497 , C07D471/04 , A61P29/00
CPC分类号: C07D471/04
摘要: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are 3-imidazoyl-pyrazolo[3,4-b]pyridine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.
摘要翻译: 提供了作为CCR1受体的有效拮抗剂并具有体内抗炎活性的化合物。 化合物是3-咪唑基 - 吡唑并[3,4-b]吡啶衍生物,可用于药物组合物,治疗CCR1介导的疾病的方法,以及用于鉴定竞争性CCR1拮抗剂的测定中的对照。
-
公开(公告)号:US20100152186A1
公开(公告)日:2010-06-17
申请号:US12708900
申请日:2010-02-19
申请人: Trevor T. Charvat , Cheng Hu , Jeff Jin , Yandong Li , Anita Melikian , Andrew M.K. Pennell , Sreenivas Punna , Solomon Ungashe , Yibin Zeng
发明人: Trevor T. Charvat , Cheng Hu , Jeff Jin , Yandong Li , Anita Melikian , Andrew M.K. Pennell , Sreenivas Punna , Solomon Ungashe , Yibin Zeng
IPC分类号: C07D401/04 , A61K31/4439 , C07D401/14 , A61K31/454 , A61K31/444 , C07D413/14 , A61K31/5377 , A61P9/10 , A61P21/00 , A61P1/00 , A61P13/12 , A61P19/02 , A61P3/04 , A61P11/00 , A61P35/00 , A61K31/437 , C07D487/04
CPC分类号: C07D401/14
摘要: Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists.
摘要翻译: 提供了作为CCR2或CCR9受体的有效拮抗剂的化合物。 动物试验表明,这些化合物可用于治疗炎症,CCR2和CCR9的标志性疾病。 化合物通常为芳基磺酰胺衍生物,并且可用于药物组合物,用于治疗CCR2介导的疾病,CCR9介导的疾病的方法,作为用于鉴定CCR2拮抗剂的测定中的对照和用于鉴定CCR9拮抗剂的测定中的对照 。
-
10.
公开(公告)号:US20080269280A1
公开(公告)日:2008-10-30
申请号:US12048814
申请日:2008-03-14
IPC分类号: A61K31/437 , C07D233/02 , C07D261/06 , C07D401/04 , A61K31/4166 , A61K31/422 , A61P37/02
CPC分类号: C07D233/32 , C07D261/06 , C07D401/04 , C07D413/06 , C07D413/14 , C07D471/04
摘要: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally monocyclic and bicyclic compounds and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
摘要翻译: 提供了作为CCR1受体的有效拮抗剂并具有体内抗炎活性的化合物。 化合物通常是单环和双环化合物,并且可用于药物组合物,用于治疗CCR1介导的疾病的方法,以及用于鉴定竞争性CCR1拮抗剂的测定中的对照。
-
-
-
-
-
-
-
-
-